

Supplementary Table S1

Table S1. NWL283 is a selective covalent inhibitor of caspase-3/7. NWL283 has a half maximal inhibitory concentration (IC_{50}) of 8 nM against caspase-3 and 21 nM against caspase-7, with minimal inhibition against other caspases.

Caspase	1	2	3	4	5	6	7	8	9	10
Enzymatic IC_{50} (nM)	290	> 10000	8	27000	> 10000	535	21	2800	41000	> 10000

Supplementary Figure S1





Figure S1. NWL283 administration leads to reduced TUNEL+NeuN+ cells. $p=0.036$, Student's T-test. $*p<0.05$, Student's T-test. $n=3$ per group; mean+SEM.

Supplementary Figure S2




Figure S2. NPCs show a cisplatin dose dependent cell death, reaching a plateau at 20µM cisplatin concentration. $n=3$; mean \pm SEM.

Supplementary Figure S3




Figure S3. The number of EDU+ cells was not different within the cortex of stroke+vehicle and stroke+NWL283 mice. $p=0.89$, Student's T-test. $n=3-4$; mean \pm SEM.

Supplementary Figure S4




Figure S4. NPCs were pre-labelled prior to stroke, using a NestinCreER^{T2}YFP^{fl} reporter mouse line. There are no NestinYFP+ cells present in the contralateral hemisphere of stroke+vehicle and stroke+NWL283 mice.